Table of Contents
- Trial overview
- Who was studied
- What was tested
- Main endpoints
- Trial design and phase
- What the results measure means
Trial overview
The provided trial investigated Aceclofenac in people with chronic back pain as part of a larger study of AP707 add-on treatment.[1] It was a Phase 3 interventional study and included 558 participants.[1] The trial status was completed.[1]
Who was studied
The study population was patients with chronic back pain.[1] The source data does not give more details about age, sex, or other joining rules, so those limits cannot be confirmed from the provided information.[1]
What was tested
Aceclofenac was one of the listed treatment options in the trial, given by oral use.[1] The trial also listed many other pain treatments and a placebo, which is a look-alike treatment with no active medicine.[1] This setup suggests that researchers were comparing pain control across several treatment arms rather than studying Aceclofenac alone.[1]
The study summary says it was an evaluation of the efficacy of AP707 as add-on treatment in patients with chronic back pain.[1] In simple terms, the study was asking whether the treatment approach helped when used together with other care.[1]
Main endpoints
The main endpoint was the change in pain level on the Numeric Rating Scale (NRS) from baseline to treatment week 14.[1] Baseline means the starting pain score before treatment begins.[1] The trial compared study arm 1, called verum, with study arm 2, called placebo.[1]
The NRS is a simple pain scale from 0 to 10, where higher numbers mean more pain.[1] This kind of endpoint helps researchers see whether treatment lowers pain over time.[1]
Trial design and phase
This was an interventional study, which means the researchers gave treatments and then measured the results.[1] It was designed as a Phase 3 trial, which is usually done in a larger group of people to compare how well treatments work.[1] The study enrolled 558 participants, showing that it was a fairly large pain study.[1]
The trial list includes several medicines used for pain, such as naproxen, paracetamol, diclofenac, ketoprofen, dexibuprofen, Aceclofenac, acemetacin, tiaprofenic acid, dexketoprofen, acetylsalicylic acid, adezunap, imipramine, celecoxib, amitriptyline, and metamizole sodium.[1] The source data does not explain how each of these treatments was assigned, so only the listed comparison set can be confirmed.[1]
What the results measure means
The main result measure was pain change over 14 weeks, which tells researchers whether patients felt better after treatment.[1] A lower NRS score would mean less pain, while a higher score would mean more pain.[1] Because the trial also focused on tolerability in its title, the study was not only about pain relief but also about how well patients could handle the treatment.[1]



